Protein-based therapeutics have transformed treatments for numerous diseases, yet their production remains highly complex and cost-intensive [1][2],[3][4]. Downstream processing (DSP), including ...

Raghu R. Chivukula, MD, Ph.D., a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is ...

Researchers headed by a team at the Centre for Genomic Regulation, Barcelona Institute of Science and Technology and at the Wellcome Sanger Institute have developed an AI tool that they say has made a ...

Researchers have developed a 'self-driving' microscope that can predict the onset of misfolded protein aggregation - a hallmark of neurodegenerative disease - as well as analyze the biomechanical ...

In Alzheimer's, Parkinson's, and type 2 diabetes, harmful protein aggregates and deposits, known as amyloid plaques, develop. There is also much evidence that these three diseases are interconnected ...

Most neurodegenerative diseases, including dementias, involve proteins aggregating into filaments called amyloids. In most of these diseases, researchers have identified the proteins that aggregate, ...

In patients with Huntington’s disease, proteins misfold and clump together. Researchers imagine the treatment could potentially someday be administered as a once-weekly injection to delay disease ...

Purdue Research Foundation has discovered compounds for inhibiting protein aggregation potentially useful for the treatment of wild-type transthyretin amyloidosis, type 2 diabetes, amyotrophic lateral ...

Parkinson's disease (PD) is an age-related, progressive neurodegenerative disorder. The hallmark of PD pathogenesis is the Lewy bodies (LBs) that accumulate in neurons in the substantia nigra region ...

Solving the structure of an amyloid protein gives new insight into limb-girdle muscular dystrophy type 3 (LGMD D3) and functional protein aggregation. LGMD D3 is a rare disease characterized by slow ...